Furthermore, various cancer types showed dysregulations in CDK2 and/or its cyclin cognates such as breast cancer, endometrial, ovarian, thyroid, lung, hepatocellular carcinomas, melanoma, lymphoma, osteosarcoma, prostate, colorectal, pancreatic cancers, neuroblastoma, and BRCA deficient cancers.20–31. This evidence concerns the gene CDK2 and pancreatic neoplasm.